Angela Alnemri

Thomas Jefferson University Hospital

Papers

2

Total Citations

16

H-Index

2

About

Angela Alnemri is a rising surgeon-scientist whose research sits at the intersection of head and neck oncology, sleep surgery, and health economics. Her work has made critical contributions to two pressing clinical questions: the safety of neoadjuvant immunotherapy in head and neck cancer and the comparative value of surgical treatments for obstructive sleep apnea (OSA). In a landmark 2023 study, she provided the first focused evidence that preoperative immune checkpoint inhibition does not significantly increase complication rates after surgery for head and neck squamous cell carcinoma (HNSCC)—a finding that directly informs evolving perioperative protocols. Her 2024 cost-analysis study further demonstrated her versatility, modeling the economic trade-offs between transoral robotic surgery (TORS) and hypoglossal nerve stimulation (HGNS) for CPAP-intolerant OSA patients, offering decision-makers a data-driven framework for resource allocation. With over a dozen citations already on her most-cited paper, Alnemri’s work is gaining rapid traction among clinicians and researchers navigating the complexities of modern head and neck care. Her ability to bridge surgical outcomes, immunotherapy safety, and cost-effectiveness marks her as a distinctive voice in the next generation of evidence-based surgical research.

Research Focus

Key Achievements

2
H-Index
2
Papers
16
Total Citations
8
Avg Citations/Paper
🏆 Most Cited Paper
Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer
13 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Thomas Jefferson University Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago